Daniel Tan Shao Weng

38PUBLICATIONS
290CO-AUTHORS
Molecular targetsArtificial life and complex adaptive systemsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Aug 11, 2026
Early EGFR inhibition triggers actionable tumour and microenvironmental remodelling in lung cancer.

|Aug 07, 2026
AI-based augmentation of oncology clinical trials.

|Jul 10, 2026
Rethinking Molecular Profiling Post First-Line Osimertinib.

|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.

|Mar 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano

|Jan 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Sarah Waliany, Alissa J Cooper, Stephen V Liu

Pageof 7

Frequent Collaborators

8 joint publications

Anders Jacobsen Skanderup

6 joint publications

Aaron C Tan

5 joint publications

Benjamin J Solomon

4 joint publications

Wan-Teck Lim